{"doc_id": "si-2020-0401-reg-1", "parent_doc_id": "si-2020-0401", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2020. \n\n(2) The citation “the Medicinal Products (Prescription and Control of \n\nSupply) Regulations 2003 to 2020” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 5) regulation 2020 (2) citation medicinal product (prescription control supply) regulation 2003 2020 includes regulation", "start_char": 640, "end_char": 919, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-reg-2", "parent_doc_id": "si-2020-0401", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "In these Regulations “Principal Regulations” means the Medicinal", "text_raw": "2. \n\nIn these Regulations “Principal Regulations” means the Medicinal \nProducts (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of \n2003).", "text_norm": "2 regulation principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003)", "start_char": 919, "end_char": 1080, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-reg-3", "parent_doc_id": "si-2020-0401", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "3. The Principal Regulations are amended by substituting for Regulation", "text_raw": "3. The Principal Regulations are amended by substituting for Regulation \n4B (inserted by Regulation 4 of the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 2) Regulations 2015 (S.I. No. 449 of \n2015)) the following: \n\n“Supply and administration of certain medicinal products by authorised \npersons \n\n4B. It shall not be a contravention of a provision of these Regulations \nfor an authorised person, in the course of his or her professional practice \nas an authorised person, to supply a person with, and to administer to the \nperson, a medicinal product specified in column 1 of the Eighth Schedule \nif, and only if— \n\n(a) \n\n(b) \n\na body recognised by the Council of the Pharmaceutical \nSociety of Ireland has issued to the authorised person a \ncertificate stating that he or she has satisfactorily completed \na course of training approved by the Registrar of the \nPharmaceutical Society of Ireland relating to the supply and \nadministration of the product and the management of any \nimmediate adverse reaction that may follow from such \nadministration, \n\nis administered \n\nthe product \nthe \nrequirements specified in columns 2 to 5 of the Eighth \nSchedule opposite the mention of the product specified in \ncolumn 1 of that Schedule, and \n\nin accordance with \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 6th October, 2020. \n\n \n \n \n \n \n \n \n \n\f[401] 3 \n\n(c) \n\nthe product is administered at the place specified in column \n6 of the Eighth Schedule opposite the mention of the product \nspecified in column 1 of that Schedule.”.", "text_norm": "3 principal regulation amended substituting regulation 4b (inserted regulation 4 medicinal product (prescription control supply) (amendment) (no 2) regulation 2015 (s.i no 449 2015)) following supply administration certain medicinal product authorised person 4b shall contravention provision regulation authorised person course professional practice authorised person supply person administer person medicinal product specified column 1 eighth schedule if-- (a) (b) body recognised council pharmaceutical society ireland issued authorised person certificate stating satisfactorily completed course training approved registrar pharmaceutical society ireland relating supply administration product management immediate adverse reaction may follow administration administered product requirement specified column 2 5 eighth schedule opposite mention product specified column 1 schedule accordance notice making statutory instrument published iris oifigiuil 6th october 2020 401 3 (c) product administered place specified column 6 eighth schedule opposite mention product specified column 1 schedule", "start_char": 1080, "end_char": 2678, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-reg-4", "parent_doc_id": "si-2020-0401", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "4. The Principal Regulations are amended by substituting for the Eighth", "text_raw": "4. The Principal Regulations are amended by substituting for the Eighth \nSchedule (as amended by Regulation 2 of the Medicinal Products (Prescription \nand Control of Supply) (Amendment) (No. 4) Regulations 2020 (S.I. No. 241 of \n2020)) the following: \n\n“EIGHTH SCHEDULE \n\nMEDICINAL PRODUCTS WHICH MAY BE SUPPLIED AND \nADMINISTERED BY AUTHORISED PERSONS PURSUANT TO \nREGULATION 4B \n\nMedicinal \nProduct \n\nRoute of \nadministra\ntion \n\nForm and \npresentatio\nn of \nproduct \nadminister\ned \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministra\ntion \n\nColumn 1 Column 2 Column 3 Column 4 Column 5 \nIntramusc\nEpinephrine \nular or \n(adrenaline\nsubcutane\n) \nous \nInjection \ninjection \n\nEpinephrine \n(adrenaline) \ninjection \npresented as \na pre-filled \nsyringe or \nampoule \n\nAdults and \nChildren: \nFor the \nemergency \ntreatment \nof \nanaphylact\nic shock \n\nColumn 6 \nAny place \n\nAny place \n\nAny place \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristic\ns of the \nproduct \nadministered \nand relevant \nnational \nguidelines \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristic\ns of the \nproduct \nadministered \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristic\n\nGlucagon \nfor \ninjection \n\nGlucagon \nhydrochlor\nide for \ninjection \n\nIntramusc\nular or \nsubcutane\nous \ninjection \n\nGlyceryl \ntrinitrate \naerosol \n\nGlyceryl \ntrinitrate \nsublingual \nspray \n\nSublingua\nl spray \n\nAdults and \nchildren: \nFor the \nemergency \ntreatment \nof \nhypoglyca\nemia \nAdults: \nFor the \nemergency \ntreatment \nof severe \n\n \n \n \n \n \n\f4 [401] \n\nHerpes \nzoster \nvaccine \nfor \ninjection \n\nangina \nattack \n\nPrevention \nof zoster \nand zosterrelated \npostherpetic \nneuralgia \n\nBy \nintramusc\nular or \nsubcutane\nous \ninjection \n\nLive, \nattenuated, \nvaricellazoster \nvirus \npowder \nand \nsolvent for \nthe \nsuspension \nfor \ninjection \n\nBy \nintramusc\nular \ninjection \nonly \n\nPrevention \nof \nseasonal \ninfluenza \n\nInfluenza \nvaccine \nsuspension \nfor \ninjection \npresented \nas a prefilled \nsyringe \n\nInfluenza \nvaccine of \na \ncompositi\non that has \nbeen \napproved \nfor use in \nthe \nEuropean \nUnion for \nthe season \nin \nquestion \n\ns of the \nproduct \nadministered", "text_norm": "4 principal regulation amended substituting eighth schedule (as amended regulation 2 medicinal product (prescription control supply) (amendment) (no 4) regulation 2020 (s.i no 241 2020)) following eighth schedule medicinal product may supplied administered authorised person pursuant regulation 4b medicinal product route administra tion form presentatio n product administer ed indication medicinal product may administer ed dosage condition administration place administra tion column 1 column 2 column 3 column 4 column 5 intramusc epinephrine ular (adrenaline subcutane ) ous injection injection epinephrine (adrenaline) injection presented pre-filled syringe ampoule adult child emergency treatment anaphylact ic shock column 6 place place place accordance summary product characteristic product administered relevant national guideline accordance summary product characteristic product administered accordance summary product characteristic glucagon injection glucagon hydrochlor ide injection intramusc ular subcutane ous injection glyceryl trinitrate aerosol glyceryl trinitrate sublingual spray sublingua l spray adult child emergency treatment hypoglyca emia adult emergency treatment severe 4 401 herpes zoster vaccine injection angina attack prevention zoster zosterrelated postherpetic neuralgia intramusc ular subcutane ous injection live attenuated varicellazoster virus powder solvent suspension injection intramusc ular injection prevention seasonal influenza influenza vaccine suspension injection presented prefilled syringe influenza vaccine compositi approved use european union season question product administered", "start_char": 2678, "end_char": 4898, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-reg-0", "parent_doc_id": "si-2020-0401", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "0.65ml for", "text_raw": "0.65ml for \nsingle \nadministratio\nn in \naccordance \nwith the \nsummary of \nproduct \ncharacteristic\ns of the \nproduct \nadministered \nand \nImmunisation \nGuidelines \nfor Ireland, as \npublished and \nupdated by \nthe National \nImmunisation \nAdvisory \nCommittee of \nthe Royal \nCollege of \nPhysicians of \nIreland", "text_norm": "0.65ml single administratio n accordance summary product characteristic product administered immunisation guideline ireland published updated national immunisation advisory committee royal college physician ireland", "start_char": 4898, "end_char": 5203, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-reg-0", "parent_doc_id": "si-2020-0401", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "0.5ml or less", "text_raw": "0.5ml or less \nfor a single \nadministratio\nn. In \naccordance \nwith the \nsummary of \nproduct \ncharacteristic\ns of the \nproduct \nadministered \nand \nImmunisation \nGuidelines \nfor Ireland, as \npublished and \nupdated by \nthe National \nImmunisation \nAdvisory \n\nThe \npremises \nof the \nretail \npharmacy \nbusiness \nin which \nthe \nauthorised \nperson \ncarries on \nprofession\nal practice \n\nAny \nsuitable \nand \nappropriat\ne place, \nhaving \nregard to \npublic \nconvenien\nce and the \nneed to \nprotect the \nhealth and \nsafety of \nthe public \nand safely \nadminister \nthe \nproduct. \n\n \n\f[401] 5 \n\nAny \nsuitable \nand \nappropriat\ne place, \nhaving \nregard to \npublic \nconvenien\nce and the \nneed to \nprotect the \nhealth and \nsafety of \nthe public \nand safely \nadminister \nthe \nproduct. \n\nCommittee of \nthe Royal \nCollege of \nPhysicians of \nIreland. \nOnly to be \nadministered \nin connection \nwith the \ncarrying on \nof the \nregistered \nretail \npharmacy \nbusiness in \nwhich the \nauthorised \nperson is \nemployed or \nengaged. \nChildren and \nadolescents \nfrom 24 \nmonths:", "text_norm": "0.5ml le single administratio n accordance summary product characteristic product administered immunisation guideline ireland published updated national immunisation advisory premise retail pharmacy business authorised person carry profession al practice suitable appropriat e place regard public convenien ce need protect health safety public safely administer product 401 5 suitable appropriat e place regard public convenien ce need protect health safety public safely administer product committee royal college physician ireland administered connection carrying registered retail pharmacy business authorised person employed engaged child adolescent 24 month", "start_char": 5203, "end_char": 6247, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-reg-0", "parent_doc_id": "si-2020-0401", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "(administered", "text_raw": "0.2 ml \n(administered \nas 0.1 ml per \nnostril). \nFor children \nwho have not \npreviously \nbeen \nvaccinated \nagainst \nseasonal \ninfluenza, a \nsecond dose \nshould be \ngiven after an \ninterval of at \nleast 4 weeks. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristic\ns of the \nproduct \nadministered \nand \n\nInfluenza \nvaccine \nnasal \nspray, \nsuspension \n\nBy \nintranasal \nadministra\ntion only \n\nPrevention \nof \nseasonal \ninfluenza \n\nInfluenza \nvaccine \n(live \nattenuated\n) nasal \nspray \nsuspension \nof a \ncompositi\non that has \nbeen \napproved \nfor use in \nthe \nEuropean \nUnion for \nthe season \nin \nquestion \n\n \n\f6 [401] \n\nImmunisation \nGuidelines \nfor Ireland, as \npublished and \nupdated by \nthe National \nImmunisation \nAdvisory \nCommittee of \nthe Royal \nCollege of \nPhysicians of \nIreland. \nOnly to be \nadministered \nin connection \nwith the \ncarrying on \nof the \nregistered \nretail \npharmacy \nbusiness in \nwhich the \nauthorised \nperson is \nemployed or \nengaged. \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristic\ns of the \nproduct \nadministered \nand relevant \nnational \nguidelines \nIn \naccordance \nwith the \nsummary of \nproduct \ncharacteristic\ns \nof the \nproduct \nadministered \nor relevant \n\nAny place \n\nAny place \n\nNaloxone \ninjection \n\nNaloxone \nNasal \nSpray \n\nIntramusc\nular \ninjection \n\nNasal \nadministra\ntion \n\nNaloxone \nhydrochlor\nide \ndihydrate \n1mg/ml \npre-filled \ninjection \n\nNaloxone \nhydrochlor\nide \ndihydrate", "text_norm": "0.2 ml (administered 0.1 ml per nostril) child previously vaccinated seasonal influenza second dose given interval least 4 week accordance summary product characteristic product administered influenza vaccine nasal spray suspension intranasal administra tion prevention seasonal influenza influenza vaccine (live attenuated ) nasal spray suspension compositi approved use european union season question 6 401 immunisation guideline ireland published updated national immunisation advisory committee royal college physician ireland administered connection carrying registered retail pharmacy business authorised person employed engaged accordance summary product characteristic product administered relevant national guideline accordance summary product characteristic product administered relevant place place naloxone injection naloxone nasal spray intramusc ular injection nasal administra tion naloxone hydrochlor ide dihydrate 1mg ml pre-filled injection naloxone hydrochlor ide dihydrate", "start_char": 6247, "end_char": 7685, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-reg-1", "parent_doc_id": "si-2020-0401", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "mg Nasal", "text_raw": "1.8 \nmg Nasal \nSpray \nSolution \n\nAdults and \nchildren: \nRespirator\ny \ndepression \nsecondary \nto known \nor \nsuspected \nnarcotic \noverdose \nAdults and \nchildren: \nRespirator\ny \ndepression \nsecondary \nto \nknown or \nsuspected \nnarcotic \noverdose \n\n \n\fPneumoco\nccal \nPolysacch\naride \nVaccine \nsolution \nfor \ninjection \n\nPneumoco\nccal \nPolysaccha\nride \nVaccine \nsolution \nfor \ninjection \n25mcg/0.5\nml in a \npre-filled \nsyringe or \nvial. \n\nBy \nintramusc\nular or \nsubcutane\nous \ninjection \n\nActive \nimmunizat\nion against \ndisease \ncaused by \nthe \npneumoco\nccal \nserotypes \nincluded \nin the \nvaccine \n\nOral \ninhalation \n\nSalbutamo\nl 100 mcg \nmulti-dose \ninhaler \n\nSalbutamo\nl \npressurised \ninhalation \nsolution \n100mcg \nmulti-dose \ninhaler \n\nAdults and \nchildren: \nFor the \nemergency \ntreatment \nof acute \nasthmatic \nattack \n\n”. \n\n[401] 7 \n\nThe \npremises \nof the \nretail \npharmacy \nbusiness \nin which \nthe \nauthorised \nperson \ncarries on \nprofession\nal practice \n\nAny place \n\nnational \nguidelines", "text_norm": "1.8 mg nasal spray solution adult child respirator depression secondary known suspected narcotic overdose adult child respirator depression secondary known suspected narcotic overdose pneumoco ccal polysacch aride vaccine solution injection pneumoco ccal polysaccha ride vaccine solution injection 25mcg 0.5 ml pre-filled syringe vial intramusc ular subcutane ous injection active immunizat ion disease caused pneumoco ccal serotypes included vaccine oral inhalation salbutamo l 100 mcg multi-dose inhaler salbutamo l pressurised inhalation solution 100mcg multi-dose inhaler adult child emergency treatment acute asthmatic attack  401 7 premise retail pharmacy business authorised person carry profession al practice place national guideline", "start_char": 7685, "end_char": 8674, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-reg-0", "parent_doc_id": "si-2020-0401", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "0.5ml for", "text_raw": "0.5ml for \nsingle \nadministratio\nn, in \naccordance \nwith the \nsummary of \nproduct \ncharacteristic\ns of the \nproduct \nadministered \nand the \nspecific \ntiming of, \nand need for \nrevaccination \nas determined \nby the \nImmunisation \nGuidelines \nfor Ireland, as \npublished and \nupdated by \nthe National \nImmunisation \nAdvisory \nCommittee of \nthe Royal \nCollege of \nPhysicians of \nIreland \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristic\ns of the \nproduct \nadministered \nor relevant \nnational \nguidelines \n\n \n \n \n\f8 [401] \n\nGIVEN under my Official Seal, \n\n30 September, 2020. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n\f[401] 9", "text_norm": "0.5ml single administratio n accordance summary product characteristic product administered specific timing need revaccination determined immunisation guideline ireland published updated national immunisation advisory committee royal college physician ireland accordance summary product characteristic product administered relevant national guideline 8 401 given official seal 30 september 2020 stephen donnelly minister health 401 9", "start_char": 8674, "end_char": 9329, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
{"doc_id": "si-2020-0401-explanatory-note", "parent_doc_id": "si-2020-0401", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 401 of 2020", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2020, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to allow for influenza vaccination to be \nadministered by registered pharmacists in places other than the premises of the \nretail pharmacy business in which they carry on their professional practice. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 5) Regulations 2020. \n\n \n \n \n \n \n \n \n \n\f10 [401] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \n52 FAICHE STIABHNA, BAILE ÁTHA CLIATH 2, \nD02 DR67. \n\nTeil: 076 110 6834 \nr-post: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \n52 ST. STEPHEN'S GREEN, DUBLIN 2, \nD02 DR67. \n\nTel: 076 110 6834 \nE-mail: publications@opw.ie \n—————— \n\n€3.00 \n\n(DH-119) 75. 10/20. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation allow influenza vaccination administered registered pharmacist place premise retail pharmacy business carry professional practice regulation may cited medicinal product (prescription control supply) (amendment) (no 5) regulation 2020 10 401 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais 52 faiche stiabhna baile atha cliath 2 d02 dr67 teil 076 110 6834 r-post publication opw.ie ------------ dublin published stationery office purchased government publication 52 st stephen green dublin 2 d02 dr67 tel 076 110 6834 e-mail publication opw.ie ------------ eur3.00 (dh-119) 75 10 20 propylon", "start_char": 9329, "end_char": 10399, "source_path": "downloads\\2020\\2020_0400.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f5490dc38a74aa49597f1685816836126571f16d7a812cfdcbb3e05dec09bee5", "cross_refs": []}
